Evidence map›Paper›PMID 25790954›Full record

SynthesisMolecular neurobiology2016

Prognostic Role of microRNA-21 Expression in Brain Tumors: a Meta-analysis.

Xiao-Yan He, Yu-Dong Liao, Xiao-Qing Guo, Robin Wang, Zhen-Yu Xiao, Yan-Gang Wang

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Molecular neurobiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Considering Exosomal miR-21 as a Biomarker for Cancer.Journal of clinical medicine · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Xiao-Yan HeDepartment of Oncology, Ganzhou People's Hospital, Ganzhou, 341000, China.
Yu-Dong LiaoGanzhou Medical School, Ganzhou, 341000, China.
Xiao-Qing GuoDepartment of Oncology, Ganzhou People's Hospital, Ganzhou, 341000, China.
Robin WangDepartment of Endocrinology and Metabolic Diseases, Affiliated Hospital of Qingdao University, Qingdao, 266006, China.
Zhen-Yu XiaoDepartment of Oncology, Ganzhou People's Hospital, Ganzhou, 341000, China. gzyxiao@126.com.
Yan-Gang WangDepartment of Endocrinology and Metabolic Diseases, Affiliated Hospital of Qingdao University, Qingdao, 266006, China. wangyg1966@yeah.net.
Ganzhou People's Hospital · CNAffiliated Hospital of Qingdao University · CNGannan Medical University · CNQingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many studies have shown that microRNAs have important roles in the development and progression of various cancers. Recent studies also showed that microRNA-21 expression may be associated with the prognosis of patients with several common cancers. However, there was still lack of evidence for the prognostic role of microRNA-21 expression in brain tumors. We performed a systemic review and meta-analysis of published and unpublished studies to assess the prognostic role of microRNA-21 expression in patients with brain tumors. PubMed, Embase, and Google Scholar databases were searched for eligible studies with data assessing the prognostic role of microRNA-21 expression in brain tumors. Pooled hazard ratios (HRs) of microRNA-21 expression for overall survival and 95% confidence intervals (CI) were calculated. Six studies from five publications were finally included into the meta-analysis. Those six studies included a total of 747 patients with brain tumors and 654 patients with gliomas. For overall survival, the pooled HR of higher microRNA-21 expression in patients with brain tumors was 1.82 (95% CI 1.29-2.58, P = 0.001). In patients with gliomas, the HR for overall survival of higher microRNA-21 expression was 1.83 (95% CI 1.09-3.09, P = 0.023). Sensitivity analysis by omitting one study by turns also showed there was no obvious influence of individual study on the pooled HRs. There was no obvious risk of publication bias in the meta-analysis. The present meta-analysis suggests that microRNA-21 is associated with the prognosis of patients with brain tumors, and high expression of microRNA-21 can predict poor prognosis in patients with brain tumors.

Indexed as

Gene Expression Regulation, NeoplasticBrain NeoplasmsGliomaHumansMicroRNAsPrognosisSurvival AnalysisMicroRNAsMIRN21 microRNA, humanBrain tumorsGliomamicroRNA-21Survival

Identifiers

PMID25790954
OpenAlexW2090406927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.